22nd April 2014 Content supplied by: CMS Technology
Vivione Biosciences Signs Agreement with CMS Technology
Vivione Biosciences, Inc., through its wholly owned subsidiary, Vivione Biosciences, LLC, announced the signing of a definitive Purchase Agreement for the RAPID B system from CMS Technology, Inc., a New ork-based firm focused on developing and delivering cost-effective, innovative solutions to mitigate pathogen risks in food, packaging and material applications. This agreement brings together two dynamic companies with exciting new technologies in microbial detection in multiple industries.
In addition to immediate revenue generation, this agreement provides Vivione commercial validation of the RAPID-B system by demonstrating its benefits to the market and opening the door for new joint development and promotional opportunities. The system’s ability to perform real-time validation studies of its products and services avails CMS immediate opportunities to prove their products efficacy. The RAPID-B system also provides a significant competitive advantage by allowing CMS to provide real time data to its customers versus its competitors who still have to wait up to 48 hours for results.
“This is clearly a win-win for both companies,” said Vivione’s Chief Executive Officer Kevin Kuykendall. “Vivione benefits by receiving both initial and recurring revenue under this agreement but also the opportunity for the RAPID-B system to be introduced into CMS’s food producing customer base. CMS benefits by being able to scale its platform and immediately initiate real-time assessments of its antimicrobial treatments and coverings that the firm is developing.”
“We are excited to acquire the RAPID-B system from Vivione,” said John Meccia, Chief Executive Officer of CMS. “We surveyed the market quite thoroughly and the RAPID-B system is a superior solution that met our stringent microbial detection requirements. We can now clearly distinguish between live and dead microbes and we have clear enumeration which allows us to show real-time efficacy in our products and services. This cutting edge technology will enhance and accelerate our ability to develop solutions that make the food we eat and the products we use safer, longer lasting and more environmentally friendly.”
Date Published: 22nd April 2014
MALDI-LinkTM in the BIOMIC® V3
ImmunoFLOW for Herpes Simplex Virus (